Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 455 Publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NGfoOXJEgXSxdH;4bYMhSXO|YYm= NYTRb5dJPTBizszN MVW0PEBp NWn3b|RDTE2VTx?= NHrHfpVMcWyuczDj[YxteyCkeTDtc5JmKHSqYX6gPVkm M3;oSlExPDl7NkSz
OVCA 429 Ml\aSpVv[3Srb36gRZN{[Xl? MljzN|AxKG6P NYLaW3NXPDhiaB?= MYrEUXNQ NWP3bY9FTGm|coXweJMhcW62YXP0JI12dHSrY3XscJVt[XJidIXtc5Ihe3CqZYLvbYR{ Mn7FNVA6QTl5Nk[=
RPMI8226 M1;pXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHzdWIyODBibl2= M1Pze|Q5KGh? NUSzfGl6TE2VTx?= MkH2TWM2OD1|MDDuUS=> MXKxNVMxPjR6OR?=
Dox40 NUjkdnQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYmxNFAhdk1? M1PrdFQ5KGh? M1XqSWROW09? MVTJR|UxRTRyIH7N MVixNVMxPjR6OR?=
MR20 M{Lwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUCxNFAhdk1? NFOwc3Y1QCCq NHLhbZRFVVOR NHHmN25KSzVyPUKwJI5O M1fJVFEyOzB4NEi5
LR5 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnGZ|kyODBibl2= MnTNOFghcA>? NHPEXYlFVVOR MVXJR|UxRTJyIH7N MWexNVMxPjR6OR?=
U266 Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PRfFExOCCwTR?= NWTKXnJtPDhiaB?= M2nsXWROW09? MlXsTWM2OD1|IH7N MYmxNVMxPjR6OR?=
IM-9 NXGzPYRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;nXZRxOTByIH7N NVvydVlCPDhiaB?= NX\hb3M{TE2VTx?= NVTmfIxvUUN3ME22JI5O MVixNVMxPjR6OR?=
Hs Sultan NVnVN4xYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:xNFAhdk1? NVj3[mdjPDhiaB?= NF;ZeVBFVVOR MlzTTWM2OD1{MDDuUS=> NYTIO4JxOTF|ME[0PFk>
PAM-LY2 MU\GeY5kfGmxbjDBd5NigQ>? MYKxNFAhdk1? M1LsWlEzKGh? Ml7xSG1UVw>? MUPJcohq[mm2czDOSk3PwkJiYXP0bZZifGmxbh?= MnnXNVE{PTB7MUO=
PAM 212 Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPMbZI2OTByIH7N MX[3NkBp NIiwZVZFVVOR M2XRN2lvcGmkaYTzJINmdGxidnnhZoltcXS7 MVWxNVM2ODlzMx?=
PAM-LY2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HQUlExOCCwTR?= NELiXG04OiCq NHnCV|JFVVOR NVHpVmRLUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MWOxNVM2ODlzMx?=
B4B8 NU\oZWd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37YZVExOCCwTR?= MWC3NkBp M2Dac2ROW09? NVT6N3JqUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MUmxNVM2ODlzMx?=
B7E3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Lld|ExOCCwTR?= M4Hrd|czKGh? MoLCSG1UVw>? MY\Jcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MmjzNVE{PTB7MUO=
UM-SCC-9 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYKxNFAhdk1? NXPJ[FBnPzJiaB?= MYDEUXNQ MX;Jcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MnHMNVE{PTB7MUO=
UM-SCC-11B NYD5[XZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojhNVAxKG6P M1rzSFczKGh? M1zlcWROW09? NVTwR3JjUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= NUnkcVRROTF|NUC5NVM>
H460 MoS5SpVv[3Srb36gRZN{[Xl? MW[xNEDPxE1? MmTvNlQhcA>? M{f4RWROW09? NWnpdnRJUW6mdXPld{BD[2xvMjDwbI9{eGixconsZZRqd25iYX7kJINt\WG4YXflJINwenKnbHH0[YQhf2m2aDDHNk1OKHCqYYPlJIFzemW|dB?= MXmxNlQ6OjFzNx?=
U266 MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;iZ3c2ODBibnevcYw> NGnPOGg1QCCq M4rhOWROW09? NVPpOmwyUW6qaXLpeJMh[2WubDDndo94fGh? NX36XIlJOTJ4M{G2NVk>
ARH77 NFP1XYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXG1NFAhdmdxbXy= MknBOFghcA>? NHn2ZnBFVVOR M1PqU2lvcGmkaYTzJINmdGxiZ4Lve5Rp NUfRU3hQOTJ4M{G2NVk>
WAD-1 NXy0PXA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\4OVAxKG6pL33s NIPOVWM1QCCq M{frSGROW09? MlT2TY5pcWKrdIOgZ4VtdCCpcn;3eIg> MYGxNlY{OTZzOR?=
U266/LR7 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HhWVUxOCCwZz;tcC=> MUe0PEBp NYO1e2FGTE2VTx?= MmHYTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MnPqNVI3OzF4MUm=
U266/dox4 NWe4S4s2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIC3cGo2ODBibnevcYw> M3nGNVQ5KGh? NF3oRmxFVVOR MXzJcohq[mm2czDj[YxtKGe{b4f0bC=> M3roUFEzPjNzNkG5
RPMI8226/LR5 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoSwOVAxKG6pL33s NEfVSlQ1QCCq NXvjTWw6TE2VTx?= MnzUTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NX;rR3hTOTJ4M{G2NVk>
H460 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLiNVAh|ryP MnH3O|IhcA>? M1riTGROW09? NGrzNZhKSzVyPUGwNEBvVQ>? MkL0NVI3OzF4MkC=
H358 NYr1OWE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmC3NVAh|ryP MWC3NkBp M4D3VWROW09? Ml;OTWM2OD15MDDuUS=> MYqxNlY{OTZ{MB?=
H322 MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[xNEDPxE1? Ml3PO|IhcA>? M3HmcWROW09? MYjJR|UxRTZ{MDDuUS=> MV[xNlY{OTZ{MB?=
H460 MYXGeY5kfGmxbjDBd5NigQ>? NEPmR40yODBibl2= NI\3bFMzPCCq NWDq[oRRTE2VTx?= MX;JcoR2[2W|IFeyMW0ueGijc3WgZZJz\XO2IHHu[EB1fWK3bHnuJIF{e2WvYnz5MYRqe2G|c3XtZox6 MlHvNVI3OzF4MkC=
LNCap-Pro5 Mlq1SpVv[3Srb36gRZN{[Xl? MVKxJO69VQ>? NEfzbnY1KGh? M4PGcWROW09? NFLzd2VUfGGkaXzpfoV{KHB3Mx?= M{fT[VE1PjF{NUOy
T29 MoDyRZBweHSxc3nzJGF{e2G7 MWi1NEBvVQ>? MnvDOFghcCB? MVjEUXNQ MVfJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MoW3NVY4PzhzN{m=
T29Kt1 MYPBdI9xfG:|aYOgRZN{[Xl? NUX1dGRZPTBibl2= MYq0PEBpKA>? MVPEUXNQ NHG4TJpKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M3rjV|E3Pzd6MUe5
HCT116 MUDBdI9xfG:|aYOgRZN{[Xl? M4LJZlUxKG6P MWi0PEBpKA>? MUjEUXNQ MlzrTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NYDlXlZDOTZ5N{ixO|k>
HKe-3 MVrBdI9xfG:|aYOgRZN{[Xl? NFrpUGk2OCCwTR?= NUXrNIdqPDhiaDC= NEfpenlFVVOR NHHJb3JKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MXSxOlc4QDF5OR?=
NB-1691 NUTRZnVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFy4RlMyKM7:TR?= M4G3O|czKGh? NHzFV5ZKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iNTW= NHjSU3IyPzZ6OU[4OC=>
CHLA-255 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV6xJO69VQ>? MYi3NkBp MmT3TY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDJn NXfEfmFsOTd4OEm2PFQ>
SK-N-AS MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULYU4J7OSEQvF2= M4C1dlczKGh? MXjJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOTBn NV\BdnFOOTd4OEm2PFQ>
NB-1691 MX;GeY5kfGmxbjDBd5NigQ>? M2TwVFExKG6P MnrrNlQhcA>? Mn;FV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KGOnbHzzJIlvKHSqZTDHNE9IOSCyaHHz[S=> M2jn[FE4Pjh7Nki0
CHLA-255 M4PPbmZ2dmO2aX;uJGF{e2G7 NWLze3I{OTBibl2= M4[zdFI1KGh? MoHJUY9l\XO2bImgdoVlfWOnczDj[YxteyCrbjD0bIUhTzBxR{GgdIhie2V? MkLMNVc3QDl4OES=
RPMI 8226 NXXlR3Y2TnWwY4Tpc44hSXO|YYm= NVf0T4h{OjBibl2= MkK2PEBp NEjOd2pUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? M1ns[VE6PDN4MEWw
MM.1S NID6bIpHfW6ldHnvckBCe3OjeR?= MViyNEBvVQ>? MYG4JIg> NGW5cWNUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? NYXyd5hpOTl2M{[wOVA>
U266 MXLGeY5kfGmxbjDBd5NigQ>? NXPmcHJFOjBibl2= NULz[2hKQCCq M4e0V3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 M4HOflE6PDN4MEWw
OPM1 NHTzV4lHfW6ldHnvckBCe3OjeR?= NFrDdYszOCCwTR?= M1jpTVghcA>? MlXJV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MVexPVQ{PjB3MB?=
INA6 MlrRSpVv[3Srb36gRZN{[Xl? MViyNEBvVQ>? M3:0cFghcA>? MUfTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MVSxPVQ{PjB3MB?=
OPM2 MnfiSpVv[3Srb36gRZN{[Xl? NFjIeFMzOCCwTR?= MnfuPEBp MmnhV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> Mo\INVk1OzZyNUC=
RPMI 8226 NITrNVFHfW6ldHnvckBCe3OjeR?= MUWyNEBvVQ>? NWPVU4tyQCCq M4Hpd2lv\HWlZYOgSG5CKHO7boTo[ZNqew>? NGTXeZoyQTR|NkC1NC=>
BaF/3 M1v6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PjfFExOCCwTR?= NECyVng1QCCq MoHNTWM2OD14LkKgcm0> M1O4OVIxOzB3Nkmy
BaF/3-p210 MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{X3OlExOCCwTR?= M3XMdlQ5KGh? NV\mW5lrUUN3ME20Mlchdk1? M{mxVFIxOzB3Nkmy
TCC-S M2XoSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWexNFAhdk1? MX:0PEBp M1r1Z2lEPTB;Mj64JI5O NH7vWnczODNyNU[5Ni=>
BaF/3 M1HlXmZ2dmO2aX;uJGF{e2G7 NHPMUFg3KG6P NIX3SlE1QCCq NWfj[IFMUW6mdXPld{BiKGe{ZXH0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 NIX1THQzODNyNU[5Ni=>
BaF/3-p210 MX\GeY5kfGmxbjDBd5NigQ>? MnPMOkBvVQ>? NHXTPXE1QCCq MnPlTY5lfWOnczDhJJNtcWeqdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=> MXSyNFMxPTZ7Mh?=
BaF/3-p210 M2TtfmZ2dmO2aX;uJGF{e2G7 M1PiSlYhdk1? M16w[|I1KGh? NFy4WVBT\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44h[W6mIITo[UBi[3Srdnn0fUBw\iCUYh?= NXnVTGp2OjB|MEW2PVI>
Raji MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVixJO69VQ>? NEPBToYzPCCq NIn5N2hT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NYLFc|d{OjFzN{C5PFg>
LCL-1 NF7ndJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4T6N|Eh|ryP M{[3XlI1KGh? NGPpd3RT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NVXvPWgzOjFzN{C5PFg>
LCL-2 NV;XSlFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDSV4x4OSEQvF2= M2LETlI1KGh? MVXS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NISzR3MzOTF5MEm4PC=>
BJAB MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS4NUDPxE1? M1;adlI1KGh? NX\5e5J7WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NYnWRmV5OjFzN{C5PFg>
SNT-13 NV3TXWRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvENUDPxE1? M{XsOlI1KGh? Mk\VVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M{fLclIyOTdyOUi4
SNT-16 NWX4d2hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj6SWpJOSEQvF2= NFvtOXEzPCCq NIX6cG5T\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NX7RT4REOjFzN{C5PFg>
Jurkat NYXF[VhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j0PFEh|ryP NGrCcFMzPCCq NGfubYJT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NEGxfokzOTF5MEm4PC=>
KAI-3 Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV6xJO69VQ>? Mn74NlQhcA>? MY\S[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M{O5NlIyOTdyOUi4
SNK-6 NYCwfZRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;mOmEyKM7:TR?= NFrH[IMzPCCq M2r5bnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MV2yNVE4ODl6OB?=
KHYG-1 NX:3epBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXGxJO69VQ>? MWiyOEBp MXfS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MU[yNVE4ODl6OB?=
SNT-16 Mn2zRZBweHSxc3nzJGF{e2G7 Mm\JNUDPxE1? MnzYOkBp MkLBTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MVSyNVE4ODl6OB?=
Jurkat M3XXPWFxd3C2b4Ppd{BCe3OjeR?= MkPKNUDPxE1? MWG2JIg> NECxUVZKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MmexNlEyPzB7OEi=
KAI-3 M2KzfWFxd3C2b4Ppd{BCe3OjeR?= NF3T[JAyKM7:TR?= MYO2JIg> MkDqTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M4G0[VIyOTdyOUi4
KHYG-1 NFLBRXBCeG:ydH;zbZMhSXO|YYm= MorqNUDPxE1? NG\ROIg3KGh? MVTJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NEP1VJozOTF5MEm4PC=>
SNT-13 MXHBcpRqfmm{YXygRZN{[Xl? MlPWNUDPxE1? MlnONlQhcA>? MoXLTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX NIDmTJAzOTF5MEm4PC=>
SNT-16 M3PQN2FvfGm4aYLhcEBCe3OjeR?= MmOxNUDPxE1? MYOyOEBp Mlr6TY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX MWOyNVE4ODl6OB?=
KAI-3 NGH3O3dCdnSrdnnyZYwhSXO|YYm= MmXyNUDPxE1? NX3MXXByOjRiaB?= M4jJcWlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? M4Dw[VIyOTdyOUi4
SNK-6 MXvBcpRqfmm{YXygRZN{[Xl? NYLqOoVlOSEQvF2= NWSzSm41OjRiaB?= MX;JcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> MY[yNVE4ODl6OB?=
RAW 264.7 M2LMRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHYV3pDOTByIH7N M{LY[VQ5KGh? MYTS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M2LUWFIzPDJ5MUW0
A375 NXLYNo1QSXCxcITvd4l{KEG|c3H5 NHSyUHEyOCCwTR?= MUCyOEBp NFv2Zm1KdmS3Y3XzJINmdGxiYYDvdJRwe2m| MYGyN|A4QTB6Mx?=
BLM NWDU[3B2SXCxcITvd4l{KEG|c3H5 MWOxNEBvVQ>? NHnIPIEzPCCq MVfJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MWCyN|A4QTB6Mx?=
A375 M{TXO2F2fG:yaHHnfUBCe3OjeR?= NYrLd4NJOTBibl2= NEXqNZkyOiCq MWnJcoR2[2W|IH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= M3jidVI{ODd7MEiz
BLM MnG3RZV1d3CqYXf5JGF{e2G7 M2n4SlExKG6P NYL1PFFjOTJiaB?= MVzJcoR2[2W|IH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= NH24RmkzOzB5OUC4Ny=>
H1299 M4ezUGFxd3C2b4Ppd{BCe3OjeR?= NHXsU405OCCwTR?= MmLyNlQhcA>? NWPBUHZpTE2VTx?= NXTqO2VwW2Wwc3n0bZpmeyCQU1PMR{Bk\WyuczD0c{BOW0NvZHXybZZm\CCrQ{mtbY5lfWOnZDDhdI9xfG:|aYO= M1\aSVI2OzJ|Nkmz
Hut-78 MVnGeY5kfGmxbjDBd5NigQ>? NETXV3AyODBibl2= MnzWNlQhcA>? MVfEUXNQ Mmq5SI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOCCneIDy[ZN{cW:w MkjsNlU3QDF|M{W=
H9 MVvGeY5kfGmxbjDBd5NigQ>? NEXlfnMyODBibl2= NH;qfFEzPCCq M17KWWROW09? M3;hR2Rwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTFiZYjwdoV{e2mxbh?= NHu4NmgzPTZ6MUOzOS=>
HH NETCWpVHfW6ldHnvckBCe3OjeR?= M{P0VFExOCCwTR?= MknuNlQhcA>? MlrhSG1UVw>? MYTkc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEzKGW6cILld5Nqd25? MXqyOVY5OTN|NR?=
Hut-78 NHPUWVNOcWe{YYTpc44hSXO|YYm= NFn4cHIyODBibl2= MV:yOEBp NUTzcZdSTE2VTx?= MmTuVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlyJR?= MkfmNlU3QDF|M{W=
HH MmS1UYloemG2aX;uJGF{e2G7 NFqxNW0yODBibl2= MlriNlQhcA>? Mn\ISG1UVw>? M4X2fHJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MTW= M17JWlI2PjhzM{O1
U937 NHzvXFlHfW6ldHnvckBCe3OjeR?= MVuxNFAhdk1? NVvTO5c4PiCq MYjJcoR2[2W|IFnMMVgh\XiycnXzd4lwdiCrbjDMVHMue3SrbYXsZZRm\CCXOUO3JI1i[3KxcHjh[4V{ MVuyOVc6OTR5Nx?=
human PBMC NFTPbYZHfW6ldHnvckBCe3OjeR?= NWnt[3c3OTByIH7N NWHoR2pmOjRiaB?= NWLpNlh4UW6mdXPld{BKVC16IILlcIVie2V? NXLXfW5YOjV5OUG0O|c>
ES6 M{DseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwMECyNUBvVQ>? M3vCc3NCVkeHUh?=
SK-UT-1 M4\MVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrp[GlEUUN3ME2wMlE3OyCwTR?= NXS0U|gyW0GQR1XS
SH-4 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLU[nRKSzVyPUCuNVc{KG6P MnPHV2FPT0WU
TE-9 NIPLV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vNW2lEPTB;MD6xPFIhdk1? NVTWV24{W0GQR1XS
A253 MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMkC4JI5O NYLScpBZW0GQR1XS
no-10 NWjuSYhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwMkGgcm0> NFzB[GRUSU6JRWK=
MMAC-SF NVLieYxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnTV|BKSzVyPUCuNlE3KG6P Ml3RV2FPT0WU
A101D MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn3TWM2OD1yLkKyOUBvVQ>? NWj6TIRqW0GQR1XS
NTERA-S-cl-D1 M1PZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMkSzJI5O M4CzZnNCVkeHUh?=
8-MG-BA M4ryUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvZTWM2OD1yLkK1JI5O MXvTRW5ITVJ?
KNS-42 MlX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7CfGpKSzVyPUCuNlU5KG6P NH7SZ5dUSU6JRWK=
LXF-289 Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\DTWM2OD1yLkK2PUBvVQ>? MoPaV2FPT0WU
OVCAR-4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz4TWM2OD1yLkK4PUBvVQ>? NE\KRmFUSU6JRWK=
LOUCY Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLZTWM2OD1yLkK5N{BvVQ>? NYjtS4NuW0GQR1XS
BB65-RCC M1Ptc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXUW5AyUUN3ME2wMlMxPCCwTR?= NHHDOGRUSU6JRWK=
D-542MG MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILkOZRKSzVyPUCuN|I6KG6P MYDTRW5ITVJ?
ONS-76 NYLHS4RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nIRWlEPTB;MD6zN{BvVQ>? NFvMb45USU6JRWK=
BB30-HNC NGTCXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnRbpNKSzVyPUCuN|M2KG6P MXHTRW5ITVJ?
KS-1 M3njUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHme5ZKSzVyPUCuN|Qhdk1? NIHme|ZUSU6JRWK=
A388 M3vaT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXFTWM2OD1yLkO1OkBvVQ>? NYrmTVA3W0GQR1XS
ES8 NIm0NWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHG5clNKSzVyPUCuOEBvVQ>? MUHTRW5ITVJ?
MZ2-MEL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[yfm1KSzVyPUCuOFA4KG6P NVKyOnE{W0GQR1XS
HCC2998 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwNEGyJI5O NX;ZOoxsW0GQR1XS
D-247MG NYrJXWc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGG1XYNKSzVyPUCuOFE{KG6P M4fhbHNCVkeHUh?=
ACN NYX3TGFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PUXmlEPTB;MD60NVchdk1? NYrRb3MxW0GQR1XS
LB2518-MEL MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwNEK1JI5O NYKw[HJoW0GQR1XS
ES1 NHXrU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HpbWlEPTB;MD60N{BvVQ>? M4fS[nNCVkeHUh?=
HCE-T MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDvO|gxUUN3ME2wMlQ{QSCwTR?= M2TnTXNCVkeHUh?=
OS-RC-2 NEjue|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLvcpJKSzVyPUCuOFQhdk1? NGjDTJRUSU6JRWK=
MFH-ino NH7CdHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX3TWM2OD1yLkS0N{BvVQ>? NWD1OGZHW0GQR1XS
OCUB-M NWnmPXhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrOOnZ5UUN3ME2wMlQ1PyCwTR?= MXXTRW5ITVJ?
CP66-MEL NEjBNGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnmyTWM2OD1yLkS3N{BvVQ>? MUnTRW5ITVJ?
LB771-HNC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDFTWM2OD1yLkS3OEBvVQ>? M4njVXNCVkeHUh?=
DSH1 MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwNEigcm0> NXHlWmJkW0GQR1XS
HUTU-80 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojHTWM2OD1yLkWzN{BvVQ>? MVPTRW5ITVJ?
CESS NXTwWXBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPOVHJKSzVyPUCuOVM5KG6P NW[3b3JHW0GQR1XS
NCI-H747 Ml7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TuTmlEPTB;MD61N|khdk1? NFrvcVlUSU6JRWK=
HT-144 MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vvWWlEPTB;MD61O|Yhdk1? NVS5WmZPW0GQR1XS
COLO-829 NHrCb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwNkG0JI5O M2XsOnNCVkeHUh?=
A4-Fuk NXXpTnhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn1fpFKSzVyPUCuOlI{KG6P NYfMN4lEW0GQR1XS
GI-ME-N M1O3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPwV3dWUUN3ME2wMlY{PCCwTR?= NVu1R2xpW0GQR1XS
LB831-BLC NH\IVYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L4RWlEPTB;MD62OFEhdk1? NUe0[5NUW0GQR1XS
HOP-62 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjXWpZKSzVyPUCuOlQ4KG6P NFTFXFVUSU6JRWK=
BB49-HNC MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\6WmlEPTB;MD62OVIhdk1? NWfiUJlZW0GQR1XS
D-336MG NWjMcXFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3OXHBKSzVyPUCuOlU4KG6P MlyyV2FPT0WU
TK10 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnQfoZJUUN3ME2wMlY4QSCwTR?= Ml;1V2FPT0WU
Ramos-2G6-4C10 M3Lv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfSbFEyUUN3ME2wMlY6OyCwTR?= M330S3NCVkeHUh?=
LB373-MEL-D MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwNzDuUS=> M3\5[HNCVkeHUh?=
SF126 NULPdmdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvMTWM2OD1yLkewNUBvVQ>? NUfzU2xDW0GQR1XS
UACC-257 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnzXHZKUUN3ME2wMlcyKG6P M3LYVXNCVkeHUh?=
KINGS-1 M1e3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYK1UYdDUUN3ME2wMlczOiCwTR?= MkfsV2FPT0WU
LS-513 NH2wfnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwN{O5JI5O MYjTRW5ITVJ?
GI-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjPXWZKSzVyPUCuO|Y1KG6P NXfHVlBRW0GQR1XS
ES7 MojDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEf2TnRKSzVyPUCuO|Y3KG6P NETHbmhUSU6JRWK=
LB2241-RCC M{f6N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL6e|NrUUN3ME2wMlgxPCCwTR?= NGfUTpdUSU6JRWK=
D-263MG NVPzUW5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwOEC3JI5O NHP1b5FUSU6JRWK=
SW684 NHmxVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\NVGlEPTB;MD64NlEhdk1? M4LpdnNCVkeHUh?=
ML-2 NU\rSHY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHK3ZVVKSzVyPUCuPFIyKG6P NYDneXZOW0GQR1XS
SK-LMS-1 NF\oOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nuSGlEPTB;MD64OVQhdk1? M2HUSHNCVkeHUh?=
TE-5 MlzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\ObYRKSzVyPUCuPFY2KG6P MYrTRW5ITVJ?
QIMR-WIL NYXIS5R5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfwW3NKSzVyPUCuPFg6KG6P NGHTOXNUSU6JRWK=
NCI-H1355 Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\t[2wyUUN3ME2wMlg6PSCwTR?= MknmV2FPT0WU
SNB75 NUjUUlJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwOUGyJI5O NUX3PFRLW0GQR1XS
RXF393 NUXyNXdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X2cWlEPTB;MD65NVQhdk1? MoLQV2FPT0WU
IST-MEL1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\OcGJKUUN3ME2wMlkyPyCwTR?= MojwV2FPT0WU
SF268 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvNPW9KSzVyPUCuPVI{KG6P NXzHe3Y1W0GQR1XS
KALS-1 NHnTNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwOUK1JI5O NEi2NGxUSU6JRWK=
HC-1 MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwOUe1JI5O NHizXHNUSU6JRWK=
SW872 NWrLVplGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1exUGlEPTB;MD65PVYhdk1? NX7ZZ21UW0GQR1XS
PSN1 NG\sSGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq4UGZKSzVyPUGuNFEhdk1? MmfEV2FPT0WU
TE-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz2TWM2OD1zLkCzJI5O MVXTRW5ITVJ?
TE-10 NGTJbHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fpNGlEPTB;MT6wN{BvVQ>? NIfLPZVUSU6JRWK=
RKO NH\2[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq1TWM2OD1zLkC2JI5O Mn3GV2FPT0WU
LC-2-ad NV\VbW5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zO[WlEPTB;MT6wPEBvVQ>? MU\TRW5ITVJ?
SK-MM-2 M4\nfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFwMEmgcm0> Mnn4V2FPT0WU
VA-ES-BJ NUXDe4tiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXMNopDUUN3ME2xMlA6KG6P MoX0V2FPT0WU
MZ7-mel NF7ReYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvzb2ZOUUN3ME2xMlA6KG6P NHrybW9USU6JRWK=
D-392MG MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrxN4lKSzVyPUGuNUBvVQ>? MV7TRW5ITVJ?
CCRF-CEM NUf4XldET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLXV|JKSzVyPUGuNVMhdk1? MUDTRW5ITVJ?
EM-2 NV7GWnJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmSwTWM2OD1zLkG2JI5O NXr5Uoh3W0GQR1XS
HAL-01 NHvISJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPpZmhKSzVyPUGuNVghdk1? NF;ZXYxUSU6JRWK=
TE-8 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHlTWM2OD1zLkG5JI5O Moi1V2FPT0WU
NCI-H1882 NUWwdW1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFwMjDuUS=> M3\m[HNCVkeHUh?=
Daudi MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzHXYRKSzVyPUGuNlIhdk1? MlTWV2FPT0WU
BL-41 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTFwMkWgcm0> M1XwR3NCVkeHUh?=
SR NV[xSIdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXtc3pKSzVyPUGuNlUhdk1? M4XG[nNCVkeHUh?=
KM12 NELyNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTFwMkegcm0> MYLTRW5ITVJ?
K5 NW\NNIY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFwMkigcm0> MVHTRW5ITVJ?
A3-KAW M3vy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{e2[mlEPTB;MT6yPEBvVQ>? NWDFNohuW0GQR1XS
CMK MnnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nRSmlEPTB;MT6yPUBvVQ>? MXHTRW5ITVJ?
Calu-6 NVO4fIpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmGyTWM2OD1zLkK5JI5O NV:5WWhxW0GQR1XS
IST-SL2 NV7aWlJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPvTWM2OD1zLkOxJI5O MoHvV2FPT0WU
OPM-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVO4bI45UUN3ME2xMlM{KG6P MYXTRW5ITVJ?
DU-4475 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFwM{[gcm0> M2TJNHNCVkeHUh?=
ECC12 NXrj[GFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTlNXFKSzVyPUGuN|chdk1? NH;veVFUSU6JRWK=
L-540 M3\Qd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHCN49KSzVyPUGuN|chdk1? NHvl[HZUSU6JRWK=
CAS-1 Mmj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnsTWM2OD1zLkO3JI5O M3H1dHNCVkeHUh?=
PF-382 NEfL[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTFwNEegcm0> MVfTRW5ITVJ?
LS-411N NYe2[pFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XvVmlEPTB;MT61N{BvVQ>? M{TCNHNCVkeHUh?=
NCI-H69 NEPUbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1yyVmlEPTB;MT61OEBvVQ>? MonFV2FPT0WU
NB12 MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTBVXZKSzVyPUGuOVYhdk1? MV;TRW5ITVJ?
HEL NVTsNZE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz6TWM2OD1zLk[xJI5O MUPTRW5ITVJ?
GCIY NWDpXm83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HlfmlEPTB;MT62NkBvVQ>? MU\TRW5ITVJ?
EHEB NEXtfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvLVZhPUUN3ME2xMlY4KG6P MXjTRW5ITVJ?
TGBC1TKB MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XXVWlEPTB;MT63NUBvVQ>? MXLTRW5ITVJ?
KURAMOCHI MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PjTGlEPTB;MT63NkBvVQ>? NHvzcFdUSU6JRWK=
U-266 NIPLToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\Ib2FKSzVyPUGuO|Yhdk1? M2DLXnNCVkeHUh?=
LC4-1 NWO1NHBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDKT|ZKSzVyPUGuO|khdk1? M2nuUnNCVkeHUh?=
NCI-H2126 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHkTWM2OD1zLkigcm0> Mkn0V2FPT0WU
NCI-H1092 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTFwODDuUS=> MUfTRW5ITVJ?
GB-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPtR49tUUN3ME2xMlgyKG6P Ml3RV2FPT0WU
MV-4-11 M3LpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFwOEKgcm0> NEXhR2pUSU6JRWK=
Becker NYHjd4Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLPZYF[UUN3ME2xMlg{KG6P M2XzUHNCVkeHUh?=
MPP-89 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1f3[mlEPTB;MT64PUBvVQ>? MUnTRW5ITVJ?
BE-13 NFfTT2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nvXWlEPTB;MT65N{BvVQ>? MkjxV2FPT0WU
697 M3q1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofMTWM2OD1zLkm5JI5O NYPIPGRFW0GQR1XS
NKM-1 MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HsfWlEPTB;MjDuUS=> M3;ad3NCVkeHUh?=
NB13 NIrjVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfrTWM2OD1{IH7N NX\lbZE1W0GQR1XS
LS-123 MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzi[3hKSzVyPUKuNFIhdk1? MoCxV2FPT0WU
NB17 NXzlbYZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjGS2xKSzVyPUKuNFQhdk1? M1LpTXNCVkeHUh?=
LAN-6 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrGTWM2OD1{LkC1JI5O NF\vXoNUSU6JRWK=
EW-24 NVvFXFNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fwVWlEPTB;Mj6wPEBvVQ>? NYT3c2JHW0GQR1XS
NOS-1 MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLt[GJmUUN3ME2yMlEyKG6P NXizVo9lW0GQR1XS
BL-70 NHXiO3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nlbGlEPTB;Mj6xNkBvVQ>? NXno[lh{W0GQR1XS
GT3TKB M4fVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJwMUKgcm0> MlS4V2FPT0WU
HH NXnUfGZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjaRVBoUUN3ME2yMlE{KG6P MU\TRW5ITVJ?
KE-37 NXfVfG5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfrepFKSzVyPUKuNVMhdk1? M2rxOXNCVkeHUh?=
MOLT-4 NUjCR2EzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i5eWlEPTB;Mj6xN{BvVQ>? MWXTRW5ITVJ?
EKVX M2W2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrQTWM2OD1{LkG0JI5O MnrtV2FPT0WU
KGN MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJwMUWgcm0> MlfUV2FPT0WU
ES4 M{THVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\XfmlEPTB;Mj6xOkBvVQ>? MmrGV2FPT0WU
SJSA-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXw[lZoUUN3ME2yMlIyKG6P NYrkdWNkW0GQR1XS
KMOE-2 NVrueWM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4WxfGlEPTB;Mj6yN{BvVQ>? NH;EXJVUSU6JRWK=
NB5 NYP3VFNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYK3NIdbUUN3ME2yMlI4KG6P MkOyV2FPT0WU
BC-1 NGW2VWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvXT49UUUN3ME2yMlMyKG6P MWDTRW5ITVJ?
NB10 MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K0N2lEPTB;Mj6zNkBvVQ>? MVzTRW5ITVJ?
RPMI-8226 M1O5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjwPW1KSzVyPUKuN|Uhdk1? NYPyfJZnW0GQR1XS
SCC-3 M37GR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W5WmlEPTB;Mj6zO{BvVQ>? M4jaPHNCVkeHUh?=
ARH-77 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJwM{igcm0> MoX1V2FPT0WU
NCI-H748 NXK2T2d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Tzc2lEPTB;Mj6zPUBvVQ>? MkDJV2FPT0WU
KU812 NWS2cFNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7CTWM2OD1{LkSyJI5O NVLaVmMyW0GQR1XS
NCI-H64 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\kTWM2OD1{LkS0JI5O MYLTRW5ITVJ?
NB69 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDmWWpWUUN3ME2yMlQ3KG6P MV3TRW5ITVJ?
KNS-81-FD MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Xt[GlEPTB;Mj60PEBvVQ>? NHLjNmNUSU6JRWK=
LB1047-RCC NWPMVJI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJwNUegcm0> NIX1eIpUSU6JRWK=
EB-3 MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3v[YZMUUN3ME2yMlY3KG6P NGnubGxUSU6JRWK=
Mo-T NVXsNWpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrlPHpYUUN3ME2yMlc1KG6P M2fwUXNCVkeHUh?=
EW-16 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\kNpJKSzVyPUKuO|Uhdk1? NULSW4hZW0GQR1XS
CTV-1 M1vBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJwODDuUS=> M2WwfnNCVkeHUh?=
ETK-1 M3raZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr0fplKSzVyPUKuPFQhdk1? NXe4ZmhpW0GQR1XS
C2BBe1 NXTiVlB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPoTWM2OD1{Lki5JI5O MYDTRW5ITVJ?
MOLT-16 M1nUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13nUWlEPTB;Mj64PUBvVQ>? MoizV2FPT0WU
SW954 NEXLclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHOS5lKSzVyPUKuPUBvVQ>? NWDOdlluW0GQR1XS
HT NFHKfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHueXFKSzVyPUOuNFIhdk1? NXvn[HRtW0GQR1XS
KARPAS-299 NFLCc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC4NlBCUUN3ME2zMlA3KG6P NGTOXpZUSU6JRWK=
MONO-MAC-6 NIPlU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjafpVWUUN3ME2zMlEhdk1? MY\TRW5ITVJ?
CGTH-W-1 NVK4O2dQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDLTWM2OD1|LkGgcm0> NHnlb2JUSU6JRWK=
SK-PN-DW MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzmeZZKSzVyPUOuNVQhdk1? MVPTRW5ITVJ?
CW-2 NEDXfFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n6V2lEPTB;Mz6yNUBvVQ>? NIW0bpdUSU6JRWK=
SK-N-DZ M{nqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnSxTWM2OD1|LkK2JI5O NXLHPWZEW0GQR1XS
NEC8 NFfkRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfHT4ZrUUN3ME2zMlM2KG6P M4POWXNCVkeHUh?=
LB996-RCC NX\nTXJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnNRXV1UUN3ME2zMlQhdk1? MUPTRW5ITVJ?
DB NWrNU2dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rMRWlEPTB;Mz60NUBvVQ>? NWfKfINCW0GQR1XS
TE-15 MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTaOIJKSzVyPUOuOFMhdk1? MXXTRW5ITVJ?
COR-L88 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTNwNEegcm0> NEDUN5VUSU6JRWK=
LAMA-84 MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jNb2lEPTB;Mz60PUBvVQ>? NWTpWG82W0GQR1XS
MEG-01 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGO1UYNKSzVyPUOuOFkhdk1? MUPTRW5ITVJ?
LOXIMVI M4DuWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPQTWM2OD1|LkWgcm0> NWW2O2UyW0GQR1XS
RPMI-8402 NEOw[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DVU2lEPTB;Mz61JI5O NV;wVWNFW0GQR1XS
KARPAS-45 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Lpd2lEPTB;Mz61OEBvVQ>? Ml62V2FPT0WU
HCC1187 NV\rb45bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D3NGlEPTB;Mz61OEBvVQ>? Mny5V2FPT0WU
MZ1-PC MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYniWGkxUUN3ME2zMlU1KG6P NYjYbW9GW0GQR1XS
no-11 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;TTWlEPTB;Mz61OUBvVQ>? M3LXbHNCVkeHUh?=
EVSA-T M2rJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLC[pJKSzVyPUOuOkBvVQ>? MVrTRW5ITVJ?
DJM-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTNwNkOgcm0> MWPTRW5ITVJ?
COLO-684 NVjENppZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH30dohKSzVyPUOuOlYhdk1? NGDlOGhUSU6JRWK=
NMC-G1 NHX1WlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3N[FlKSzVyPUOuOlghdk1? M2f5VHNCVkeHUh?=
LC-1F MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX6TlEyUUN3ME2zMlc1KG6P NEPmZXhUSU6JRWK=
RL95-2 NFfVS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f2UWlEPTB;Mz63PUBvVQ>? M1zIT3NCVkeHUh?=
COLO-320-HSR Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjYOIJKSzVyPUOuPVIhdk1? NH7leWxUSU6JRWK=
RCC10RGB M{fn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvzTWM2OD1|LkmzJI5O Ml31V2FPT0WU
HD-MY-Z NIfWR5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTNwOUOgcm0> M4nnW3NCVkeHUh?=
NCI-H2141 NFuwRZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn3eJNzUUN3ME20MlA2KG6P MmTtV2FPT0WU
K-562 M1PDNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jpWWlEPTB;ND6xNkBvVQ>? NF\6Vm9USU6JRWK=
NCI-H1648 MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\rTWM2OD12LkGzJI5O NUL3NYRuW0GQR1XS
OMC-1 Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7BTWM2OD12LkG4JI5O NFTFcYZUSU6JRWK=
LB647-SCLC NXLtcY96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTpbINtUUN3ME20MlIzKG6P NX7O[YpDW0GQR1XS
TE-12 NVG1Oo5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PhbGlEPTB;ND6yOUBvVQ>? NH3ObW1USU6JRWK=
NOMO-1 NUnWcZZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTRwM{Ogcm0> NYP6fmlkW0GQR1XS
Raji Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4P2T2lEPTB;ND60OkBvVQ>? MnPnV2FPT0WU
NALM-6 Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn1SVdKSzVyPUSuOFkhdk1? NYT5XGpOW0GQR1XS
HL-60 M1nBWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm1VFNKSzVyPUSuOlchdk1? Mn3vV2FPT0WU
IST-SL1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfqTWM2OD12Lk[4JI5O NG\LcmZUSU6JRWK=
MHH-PREB-1 NV3k[YhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXWxUIQ5UUN3ME20Mlg3KG6P MlLFV2FPT0WU
MHH-NB-11 NYnJOIxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\KTWM2OD12LkmxJI5O NH\Ve5ZUSU6JRWK=
JiyoyeP-2003 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\yTWM2OD13IH7N MXvTRW5ITVJ?
SBC-1 M4TPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof1TWM2OD13LkCxJI5O MVrTRW5ITVJ?
CHP-126 NHHCZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Xhc2lEPTB;NT6wOkBvVQ>? MVjTRW5ITVJ?
LU-139 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzj[IhqUUN3ME21MlE{KG6P NVjJSnJ3W0GQR1XS
NCI-SNU-5 M17GNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTVwMUegcm0> M4\vUXNCVkeHUh?=
SW962 NHL0TmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELjPItKSzVyPUWuNlEhdk1? M1XLc3NCVkeHUh?=
EW-1 NIK5RlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LNfmlEPTB;NT6zNUBvVQ>? NUPaenhbW0GQR1XS
NCI-H1417 NE\Fb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTVwNUGgcm0> NUHQ[JhSW0GQR1XS
LU-65 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELue4VKSzVyPUWuPFQhdk1? Mli5V2FPT0WU
D-502MG MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTZwM{egcm0> NXv6T3FVW0GQR1XS
BC-3 NEXUXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjH[IxKSzVyPU[uOlEhdk1? M3fUXXNCVkeHUh?=
GDM-1 MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHSb2JtUUN3ME22Mlc4KG6P NXfBeXlNW0GQR1XS
NCI-H2196 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17EXmlEPTB;Nj64JI5O M2e5SnNCVkeHUh?=
NB1 NHjrVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjxcVNKSzVyPU[uPFghdk1? MVTTRW5ITVJ?
NCI-H345 NITCNJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\FOpBKSzVyPUeuNkBvVQ>? M13lZXNCVkeHUh?=
SU-DHL-1 NFXSRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTdwMkSgcm0> M3vBS3NCVkeHUh?=
JVM-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmq3TWM2OD15LkK4JI5O Mny1V2FPT0WU
LU-134-A MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTdwM{mgcm0> M4iwS3NCVkeHUh?=
NCI-H1694 NYfMZllST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTdwNUigcm0> MlX3V2FPT0WU
NCI-SNU-16 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLRR2FVUUN3ME23MlY2KG6P NWe3R21UW0GQR1XS
L-363 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfGV2tEUUN3ME23Mlchdk1? NFnDcpVUSU6JRWK=
KG-1 M2LOZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvNTVJnUUN3ME23Mlk1KG6P M{\yW3NCVkeHUh?=
MN-60 MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq0TWM2OD16LkG0JI5O MXfTRW5ITVJ?
NB6 NWnZWmNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jpV2lEPTB;OD60PEBvVQ>? NXTTPYZ5W0GQR1XS
MLMA NUHF[mRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYe4c2VJUUN3ME24Mlg2KG6P M4rIV3NCVkeHUh?=
ATN-1 MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\JdXJKSzVyPUiuPFkhdk1? M2fXOHNCVkeHUh?=
SK-NEP-1 NHLROnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TCTGlEPTB;OT6wNUBvVQ>? MYDTRW5ITVJ?
DMS-114 NYPESG1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTlwNkKgcm0> NUjBe4VbW0GQR1XS
CTB-1 M3jKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LxdmlEPTB;OT62O{BvVQ>? MWDTRW5ITVJ?
NCI-H2081 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTFyLkC5JI5O MVTTRW5ITVJ?
ES5 NVnrR4diT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFyLkO4JI5O NWXWT|RNW0GQR1XS
HCC1599 NYe4T3ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTjcVZ5UUN3ME2xNU46OSCwTR?= NVzwNWxvW0GQR1XS
NCI-H23 NIrRZ3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\HPGlEPTB;MUKuNVIhdk1? MmO2V2FPT0WU
NCI-H1581 M13Ob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX3[pFxUUN3ME2xNk4zQCCwTR?= NXiyWG1{W0GQR1XS
JVM-3 NF3t[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEm4fnNKSzVyPUGyMlk6KG6P M2Tad3NCVkeHUh?=
NCI-SNU-1 M3zEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\IeVRKSzVyPUGzMlE6KG6P MVTTRW5ITVJ?
NB7 M4fVV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGC4[FJKSzVyPUG1MlkzKG6P M1njd3NCVkeHUh?=
JAR MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fMRmlEPTB;MU[uNVMhdk1? Mmi0V2FPT0WU
TGW MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTF4LkS4JI5O Mn\tV2FPT0WU
U-87-MG M4X1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D6cWlEPTB;MU[uO|Yhdk1? MUHTRW5ITVJ?
NCI-H1436 MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrrRYZKSzVyPUG3MlAyKG6P NWCyOmVOW0GQR1XS
GOTO MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\JbGlEPTB;MUeuNFYhdk1? MlfXV2FPT0WU
COLO-800 NFfyXGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLUS|N7UUN3ME2xO{43PCCwTR?= M{jrdnNCVkeHUh?=
MFM-223 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDWTWM2OD1zNz65NUBvVQ>? NGLueZBUSU6JRWK=
EW-18 NIDMbFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF5Lkm2JI5O NYrUWFQyW0GQR1XS
NB14 NXnCblFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTF5Lkm4JI5O MmL1V2FPT0WU
EB2 M{i1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\iTWM2OD1zOD6wPEBvVQ>? NV3UfoZpW0GQR1XS
EoL-1- NYq4PYhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{O1cmlEPTB;MUiuN|Ehdk1? MoT5V2FPT0WU
NCCIT NF7ab3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PBUGlEPTB;MUiuN|Yhdk1? NVHlN5Z4W0GQR1XS
DG-75 MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjTbpZKSzVyPUG4MlYyKG6P M1\XTnNCVkeHUh?=
HCC2218 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfZTWM2OD1zOT61JI5O M2TH[3NCVkeHUh?=
TE-6 MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn0eXpKSzVyPUKwMlA5KG6P NYD2RWxTW0GQR1XS
SF539 M2DzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJyLk[3JI5O M4\5cXNCVkeHUh?=
NCI-H446 MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXoTWM2OD1{MT6xPEBvVQ>? MX7TRW5ITVJ?
IST-MES1 NVjONnFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TkSWlEPTB;MkKuO|chdk1? NFfB[ZRUSU6JRWK=
NCI-H82 Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jHeGlEPTB;MkOuNFIhdk1? NHHJenZUSU6JRWK=
HCC2157 NFzmcXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TNb2lEPTB;MkOuNVMhdk1? MmjSV2FPT0WU
EW-12 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDPZWwzUUN3ME2yN{4yPyCwTR?= MW\TRW5ITVJ?
SIMA MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJ|LkO4JI5O MWHTRW5ITVJ?
DOHH-2 NE\1[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PLXWlEPTB;MkOuOFUhdk1? M2qwdHNCVkeHUh?=
IM-9 NYG2ZnVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTG[|ZKSzVyPUKzMlU1KG6P MX;TRW5ITVJ?
EC-GI-10 NGrxfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\qOJpyUUN3ME2yOE4zOyCwTR?= MXHTRW5ITVJ?
HDLM-2 Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{T4SGlEPTB;MkSuOVQhdk1? M4DWVXNCVkeHUh?=
LS-1034 M3;mXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPJb21KSzVyPUK1Mlc2KG6P M4Pt[nNCVkeHUh?=
REH NUG4UWN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEj4NpRKSzVyPUK2MlQyKG6P Mk\iV2FPT0WU
LU-165 NEe4fotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[wTWM2OD1{Nj63NkBvVQ>? MXzTRW5ITVJ?
NH-12 NX;UU5pmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJ5Lk[3JI5O MmfSV2FPT0WU
WSU-NHL NVnIPZVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTtTWM2OD1{OD6zPUBvVQ>? MWLTRW5ITVJ?
ECC4 NIL2fI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVGyUpQ5UUN3ME2yPE44QSCwTR?= M3rsUXNCVkeHUh?=
OCI-AML2 MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\CS2lEPTB;MkmuOlkhdk1? MmXlV2FPT0WU
EW-3 Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTNyLkW5JI5O NXrYdWNLW0GQR1XS
NCI-H526 NIXkWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W5fWlEPTB;M{KuOVQhdk1? NXvkUpdiW0GQR1XS
NCI-H719 NETGVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fUNGlEPTB;M{SuN|Ehdk1? NEXh[XRUSU6JRWK=
KARPAS-422 Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzoWlBkUUN3ME2zOU4xPCCwTR?= NHXNfY5USU6JRWK=
SK-MEL-1 M17me2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTN3LkG3JI5O MnmxV2FPT0WU
ES3 MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\qTWM2OD1|NT6xPUBvVQ>? MmXhV2FPT0WU
UACC-812 NUPpO5R4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1qxO2lEPTB;M{WuOFQhdk1? NWnXbndHW0GQR1XS
C8166 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTN3Lkegcm0> NU\RVmNLW0GQR1XS
MDA-MB-134-VI NHjpWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLzTWM2OD1|NT64O{BvVQ>? Mn3nV2FPT0WU
D-283MED M2DJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjWT3hIUUN3ME2zO{44QSCwTR?= MYLTRW5ITVJ?
SHP-77 MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrzboJKSzVyPUO4MlA{KG6P NVP3V|B5W0GQR1XS
NCI-H2227 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTRyLkS5JI5O M3OzZXNCVkeHUh?=
SKM-1 MmPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M320e2lEPTB;NEKuOlMhdk1? M2TTWnNCVkeHUh?=
L-428 NGXM[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTR|Lki2JI5O MnPzV2FPT0WU
RPMI-6666 NEjvfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17FOGlEPTB;NEWuPFkhdk1? MX;TRW5ITVJ?
NCI-H716 NF\6RYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPWTWpKSzVyPUS4MlgyKG6P MkTCV2FPT0WU
DMS-79 M3Xs[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTVyLkexJI5O MVHTRW5ITVJ?
RS4-11 MnvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHvTWM2OD13MD64PEBvVQ>? NYi3TItWW0GQR1XS
NCI-H720 M1HDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1G1NGlEPTB;NUGuNVEhdk1? NVezUZJxW0GQR1XS
MC-CAR M1;MZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnENGdCUUN3ME21NU42OiCwTR?= MVjTRW5ITVJ?
TALL-1 Ml\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\ubYZKSzVyPUWzMlkyKG6P NHXnXnBUSU6JRWK=
NCI-N87 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLlNpNvUUN3ME21OE4yQCCwTR?= MXjTRW5ITVJ?
P30-OHK NFfiOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy4NmxMUUN3ME21OE43OSCwTR?= NFTaRWpUSU6JRWK=
LP-1 NU\oXlRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{m2XmlEPTB;NkGuNlghdk1? MlTRV2FPT0WU
YT NWnHTVA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT5SZRLUUN3ME22NU45KG6P M33VTHNCVkeHUh?=
MRK-nu-1 NH\tO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7UTWM2OD14MT64NkBvVQ>? NXTLVmRqW0GQR1XS
BT-474 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDtTY5KSzVyPU[1JI5O MkHFV2FPT0WU
NCI-H322M MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjXTWM2OD14Nj6xNUBvVQ>? MYfTRW5ITVJ?
NCI-H128 MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTd2Lke3JI5O NVPGd5ZzW0GQR1XS
KMS-12-PE MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfrW3NkUUN3ME23Ok4zPCCwTR?= NVOwe5VjW0GQR1XS
KP-N-YS NViwTZZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTd4Lke0JI5O MlfuV2FPT0WU
ALL-PO NEe0ZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW2TWM2OD15Nz62OkBvVQ>? MojGV2FPT0WU
EW-13 MnKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTd5Lke2JI5O M1vxbXNCVkeHUh?=
EW-11 M4jwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTd6LkWyJI5O MnvTV2FPT0WU
SK-N-FI MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRThyLkKgcm0> NXKyVJBiW0GQR1XS
CAL-148 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvYfW1KSzVyPUixMlg1KG6P MYLTRW5ITVJ?
RL Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTh4LkC5JI5O MYnTRW5ITVJ?
AM-38 NH\rZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4e4[WlEPTB;OEiuNFghdk1? NUPCZ3dVW0GQR1XS
RH-1 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTl7Lki1JI5O Mk\JV2FPT0WU
NCI-H1770 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHYfYhnUUN3ME2xNFIvPDlibl2= M1LsenNCVkeHUh?=
SIG-M5 M3\UOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L2VmlEPTB;MUC1MlA3KG6P MlLrV2FPT0WU
GR-ST M1XpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLLTWM2OD1zMUOuN|Qhdk1? MlrnV2FPT0WU
ST486 NXfWdHVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTFzND6wOkBvVQ>? MX\TRW5ITVJ?
NCI-H1650 M1jyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3DOppKSzVyPUGxOU4zQSCwTR?= MmLJV2FPT0WU
MHH-CALL-2 NWCwOmxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TLWmlEPTB;MUG1Mlchdk1? MnHDV2FPT0WU
BV-173 M2\mbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTF{Mj63NUBvVQ>? NHPQUY9USU6JRWK=
MC116 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\IU|RKSzVyPUG0PE45PSCwTR?= Mo\2V2FPT0WU
NCI-H524 MmDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHwTWM2OD1zNUmuNUBvVQ>? M4PieXNCVkeHUh?=
SCLC-21H MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnBZoFFUUN3ME2xOVkvPDFibl2= NH2yUIFUSU6JRWK=
NCI-H1304 NUL1[4N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\ROmlEPTB;MU[5MlIyKG6P NELDNVVUSU6JRWK=
NCI-H510A MlL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL0TWM2OD1zOEWuN|chdk1? NIL4cnpUSU6JRWK=
NCI-H209 NHrD[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK2U21KSzVyPUG5Ok42OiCwTR?= MUnTRW5ITVJ?
KM-H2 MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moq3TWM2OD1zOUeuNFUhdk1? NWXrZpZZW0GQR1XS
NCI-H1395 NF[zWIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfBN4tKSzVyPUKxNE4yOyCwTR?= NILrdZlUSU6JRWK=
NCI-H1155 MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJ|MD6zNkBvVQ>? NHTW[ZhUSU6JRWK=
COR-L279 NYnpcoNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fITmlEPTB;MkWyMlE4KG6P NFmzboRUSU6JRWK=
NCI-H1299 Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGm3OZJKSzVyPUK2NU44OSCwTR?= NHj5Z|dUSU6JRWK=
EW-22 M2DQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUP1UoNlUUN3ME2yOlMvPzVibl2= MV7TRW5ITVJ?
SK-MEL-2 NUK3TXNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHWUFBHUUN3ME2yPFEvQSCwTR?= M1PVTXNCVkeHUh?=
KASUMI-1 MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzpNGtyUUN3ME2yPFMvODVibl2= NIPIWZJUSU6JRWK=
NCI-H187 NHrnNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj5[ZVKSzVyPUK4O{4xQCCwTR?= M13HbHNCVkeHUh?=
NCI-H2171 M3nPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3DTWM2OD1{OEiuPVIhdk1? NEX6bG9USU6JRWK=
LNCaP-Clone-FGC NXTKT2l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XtUGlEPTB;Mkm1MlI3KG6P NWHOU2k4W0GQR1XS
NCI-H1522 M3LCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTNyNz6wOUBvVQ>? Ml\kV2FPT0WU
SCH M1n4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD5TWM2OD1|MkKuNlIhdk1? NYHKUnhDW0GQR1XS
THP-1 MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfPTWM2OD1|MkKuOkBvVQ>? Mo\sV2FPT0WU
SNU-C1 NFrpUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\DO2ZKSzVyPUO2Nk4xQSCwTR?= Ml24V2FPT0WU
CA46 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnWZo1KSzVyPUO3N{43OyCwTR?= NHTBbFVUSU6JRWK=
NCI-H1963 MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTN6Nj6xPUBvVQ>? MVfTRW5ITVJ?
DEL NVrafZdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\pZ4ZKSzVyPUO5NU4zPyCwTR?= M3H6VHNCVkeHUh?=
TUR MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoSwTWM2OD1|OU[uOlEhdk1? M2njRnNCVkeHUh?=
NCI-H226 M1XJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jlcGlEPTB;NECzMlI{KG6P NVu1[VVIW0GQR1XS
COLO-668 NIn2TmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;0TWM2OD12MEOuOVchdk1? MWHTRW5ITVJ?
CPC-N MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nvfmlEPTB;NECzMlc4KG6P MYjTRW5ITVJ?
NCI-H889 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTR4MT65NkBvVQ>? M3XwfHNCVkeHUh?=
J-RT3-T3-5 MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3WUoZKUUN3ME21N|IvPTdibl2= MVPTRW5ITVJ?
MSTO-211H NYGwSJh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTV5ND6yOkBvVQ>? NGq5cItUSU6JRWK=
SCC-15 NFHM[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHNZY9bUUN3ME22OlcvPDdibl2= NVjRR5djW0GQR1XS
SUP-T1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTZTWM2OD14OE[uNFQhdk1? NXzIS4pzW0GQR1XS
DMS-153 NHzpPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LheGlEPTB;N{S2Mlg{KG6P MVjTRW5ITVJ?
MS-1 M1XUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfPVHpKSzVyPUe1PU41OiCwTR?= M{i1[HNCVkeHUh?=
TC-YIK MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\rPWlEPTB;N{ixMlAyKG6P M1nI[3NCVkeHUh?=
RPMI-8866 NH\teGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2G0bWlEPTB;MUCwOk4zQCEQvF2= MV;TRW5ITVJ?
KY821 MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTOZmxKSzVyPUGwN|YvODRizszN MXHTRW5ITVJ?
P31-FUJ MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFzMUKuO|Uh|ryP M1LRUnNCVkeHUh?=
COLO-824 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTF{NkGuO|gh|ryP MnTwV2FPT0WU
U-698-M MmPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWG2d|R{UUN3ME2yNlYzNjF3IN88US=> NGjN[2ZUSU6JRWK=
TE-441-T M4DMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHWfVZHUUN3ME2yOVIyNjdizszN M3nNWXNCVkeHUh?=
IMR-5 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvhTWM2OD1|NEC5MlYzKM7:TR?= NVi0PGU6W0GQR1XS
NCI-H1838 NWPmWppvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTRzOE[uN|Ih|ryP M1:2TXNCVkeHUh?=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
phospho-PERK / ATF-4; 

PubMed: 15509775     


UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against phospho-PERK, ATF-4. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. 

GRP-78 / GADD-34; 

PubMed: 15509775     


UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against GRP-78, and GADD-34. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. 

pro-caspase-12 / pro-caspase-3; 

PubMed: 15509775     


MEFs were treated with PS-341 for the indicated time periods, and the whole-cell extracts were prepared. Fifty-microgram aliquots of proteins were probed with polyclonal antibodies against caspase 12 and caspase 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. 

pro-caspase-9; 

PubMed: 15509775     


UMSCC-23 cells were pretreated with or without Tiron for 30 min and then treated with PS-341 for the indicated time periods. The whole-cell proteins were probed with polyclonal antibodies against caspases 9 and 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin.

p-IκBα / IκBα; 

PubMed: 20335171     


PS-341 induces IκBα degradation in human lung cancer cells. The given cells lines were treated with the indicated concentrations of PS-341 for 8 h (C). After treatment, the cells were then subjected to preparation of whole-cell protein lysates and subsequent Western blot analysis. 

COX-2 / cIAP2; 

PubMed: 24085292     


NCI-H157 cells were incubated with PS-341 (50 nM) or MG132 (20 μM) for the indicated times.  Total cellular extracts were subjected to Western blot analysis for COX-2, cIAP2 and actin. 

15509775 20335171 24085292
Immunofluorescence
Vimentin; 

PubMed: 19010849     


ES-2 ovarian cancer cells were incubated with 5nM PS-341, 10 μM NK84 or the combination of both for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). 

Ubiquitin; 

PubMed: 19010849     


IOSE-29 cells were incubated with 20nM PS-341 for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). 

19010849
Growth inhibition assay
Cell viability ; 

PubMed: 20571067     


A, TSA enhanced the cell death induced by PS-341 in UMSCC1 cells. Cell viability was determined by the trypan blue exclusion assay. The assays were performed with triplicate samples, and the results are representative of three independent experiments (**P < 0.01). Error bars depict standard deviation. B, C and D, TSA enhanced PS-341-induced cell death in UMSCC23 (B), UMSCC9 (C), and FaDu (D). **P < 0.01.

20571067
ELISA
IL-8; 

PubMed: 24085292     


NCI-H157 cells were treated with PS-341 (10–100 nm) or TNF-α (10 ng/ml) as a positive control for 24 h. IL-8 concentrations in media were determined by ELISA. Data represent the mean ± S.D. of triplicates. **, p < 0.05 versus control cells. Results are representative of three separate experiments.

24085292
In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]
- Collapse

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]
- Collapse
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]
- Collapse
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4
CAS No. 179324-69-7
Storage powder
in solvent
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03993262 Not yet recruiting Drug: Bortezomib|Drug: Placebo Autoimmune Encephalitis Jena University Hospital October 1 2019 Phase 2
NCT00425503 Completed Drug: PS-341 (bortezomib) Prostate Neoplasms Baylor College of Medicine|Millennium Pharmaceuticals Inc. December 2001 Phase 2
NCT00025376 Completed Drug: PS-341|Procedure: Tumor Biopsy Kidney Cancer University of Chicago|National Cancer Institute (NCI) October 2001 Phase 2
NCT00237627 Completed Drug: PS-341|Drug: Doxil|Drug: Velcade Breast Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Ovarian Cancer|Unspecified Adult Solid Tumor Protocol Specific UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) May 2001 Phase 1|Phase 2
NCT00006773 Terminated Drug: bortezomib Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor National Cancer Institute (NCI) May 2001 Phase 1
NCT00373906 Completed Drug: Bortezomib (Velcade) MALT Lymphoma Medical University of Vienna Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

selleck catalog

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

  • Pan Proteasome Inhibitor

    Ixazomib (MLN2238) : β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.

  • FDA-approved Proteasome Inhibitor

    Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.

  • Newest Proteasome Inhibitor

    Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

Related Proteasome Products

  • VR23 New

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin New

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat (BB-2516) New

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • MG-132

    MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • Ixazomib Citrate (MLN9708)

    Ixazomib Citrate (MLN9708) immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID